DAX25.479 -1,3%Est506.325 -1,1%MSCI World4.343 -0,1%Top 10 Crypto8,3400 +0,5%Nas25.756 -1,4%Bitcoin55.754 -0,4%Euro1,1428 -0,1%Öl73,78 +2,5%Gold4.147 -0,4%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 TKMS thyssenkrupp Marine Systems TKMS00 SpaceX A42D4F Infineon 623100 Siemens Energy ENER6Y NVIDIA 918422 SAP 716460 Bayer BAY001 Lufthansa 823212 Deutsche Telekom 555750 Micron Technology 869020 Volkswagen (VW) vz. 766403 Deutsche Bank 514000 Allianz 840400 RENK RENK73
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
KI-Aktien unter Druck: Dow in Rot -- DAX leichter -- TKMS erhält NATO-Rekordauftrag -- Samsung, Sandisk, Micron, Microsoft, Telekom, Siemens Energy, Vertex, Rivian, LG, AMD, SpaceX im Fokus
Top News
So entwickeln sich Bitcoin & Co. am Nachmittag So entwickeln sich Bitcoin & Co. am Nachmittag
Novo Nordisk-Aktie im Plus: Pharmariese kooperiert mit Vivani Medical bei Semaglutid-Implantat Novo Nordisk-Aktie im Plus: Pharmariese kooperiert mit Vivani Medical bei Semaglutid-Implantat
Suche...
Jetzt kostenlos
bei finanzen.net anmelden
Watchlists & Musterdepots Tools & integriertes Trading Newsletter, Trading-Desk uvm.
Schon einen Account? Anmelden
Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

AB SCIENCE Aktie

Kaufen
Verkaufen
AB SCIENCE Aktien-Sparplan
0,7500 EUR -0,0050 EUR -0,66 %
STU
0,8450 EUR -0,0318 EUR -3,63 %
LSE
finanzen.net zero
AB SCIENCE jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.56,62 Mio. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA1CXBG

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINFR0010557264

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolABSCF

AB SCIENCE Aktien News

DatumMeistgelesen
GlobeNewswireAB Science announces issuance of a Canadian patent protecting the composition of matter of AB8939, including its use in the treatment of acute myeloid leukemia, with protection until 2036
GlobeNewswireAB Science announces EMA approval of Masivet shelf-life extension to 4 years
GlobeNewswireAB Science announces the settlement delivery of its latest capital increase for €1.8 million
Wer­bungAB SCIENCE-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
GlobeNewswireAB Science announces the successful completion of a EUR 1.8 million private placement
GlobeNewswireAB Science receives Chinese patent protecting masitinib in the treatment of Covid-19 until 2041, adding one more indication with long term intellectual property protection
GlobeNewswireAB Science today reports a new publication in the scientific journal PLOS One, showing promising neuroprotective effects of masitinib
GlobeNewswireAB Science reports its revenues for the year 2024 and provides an update on its activities
GlobeNewswireAB Science will present new data from masitinib clinical program in ALS in two presentations at the 2025 ENCALS Annual Meeting
GlobeNewswireAB Science will publish its 2024 annual financial report on May 9, 2025
GlobeNewswireAB Science announces that EMA granted orphan drug status to AB8939 for the treatment of acute myeloid leukemia
GlobeNewswireAB Science receives notice of allowance for Unites States patent covering masitinib until 2040 in the treatment of sickle cell disease
GlobeNewswireAB Science: Article from the leading publication Life Sciences Magazine featuring masitinib and its Phase 3 principal investigator, the neurologist Patrick Vermersch
GlobeNewswireAB Science today provides an update on its masitinib platform
GlobeNewswireAB Science will host a live webcast on Tuesday January 28, 2025, from 5.30pm to 6.45pm CET
GlobeNewswireAB Science will participate in the Biomed Forum investors conference
GlobeNewswireAB Science provides a summary of the webcast held on December 16, 2024
GlobeNewswireAB Science will host a live webcast on Monday December 16, 2024, from 5.30pm to 6.30pm CET
GlobeNewswireAB Science receives notice of allowance for European patent covering masitinib until 2040 in the treatment of sickle cell disease
GlobeNewswireAB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS
GlobeNewswireAB Science: Revenues for the first half of 2024 and update on AB Science’s activities
GlobeNewswireAB Science announces a slight delay in the publication of its 2024 half-year financial report
GlobeNewswireAB Science provides an update on the microtubule program AB8939 and in particular the ability of AB8939 to generate response on MECOM rearrangement
GlobeNewswireAB Science provides an update on the development of masitinib in progressive forms of multiple sclerosis post ECTRIMS 2024
GlobeNewswireAB Science announces positive results of its Phase 2 study evaluating masitinib in Covid-19
GlobeNewswireAB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS
GlobeNewswireAB Science is providing a summary of the live webcast held on May 30, 2024, giving an update on the application for conditional marketing authorization of masitinib in ALS
GlobeNewswireAB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS
GlobeNewswireAB Science reports its revenues for the year 2023 and provides an update on its activities
GlobeNewswireAB Science announces issuance of a European patent for masitinib in the treatment of severe mastocytosis with protection until 2036
GlobeNewswireAB Science : The Paris Court of Appeal confirms the acquittal of the CEO of AB Science, Alain Moussy, and reduces the amount of the financial penalty imposed on AB Science
GlobeNewswireAB Science announces a slight delay in the publication of its 2023 annual financial report
GlobeNewswireAB Science announces that Health Canada has granted eligibility for reconsideration request for masitinib in ALS
GlobeNewswireAB Science: New research shows that masitinib limits neuronal damage in a model of neuroimmune-driven neurodegenerative disease
GlobeNewswireAB Science provides a summary of the live webcast held on March 4, 2024 giving an update on AB Science development
GlobeNewswireAB Science announces that two financial analysis firms, DNA Finance and In Extenso Finance, have initiated coverage of the Company
GlobeNewswireAB Science will host a live webcast on Monday March 4, 2024, from 6.30pm to 7.30pm CET
GlobeNewswireAB Science will host a live webcast on Monday March 4, 2024, from 6.30pm to 7.30pm CET
GlobeNewswireAB Science announces that Health Canada has issued a Notice of Non-Compliance-Withdrawal (NON/w) for masitinib in ALS
GlobeNewswireAB Science announces an update in the marketing authorization application of masitinib in amyotrophic lateral sclerosis at the European Medicines Agency
GlobeNewswireAB Science receives notice of allowance for European patent covering masitinib until 2036 in the treatment of mastocytosis

AB SCIENCE News

AB SCIENCE News: auf dieser Seite finden Sie alle AB SCIENCE News und Nachrichten zur AB SCIENCE Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch AB SCIENCE News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um AB SCIENCE News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.